Vivos Therapeutics Registers 3.96M Shares for Resale by Institutional Investor Armistice Capital

summarizeSummary

Vivos Therapeutics filed an S-3 to register 3.96 million shares for resale by Armistice Capital, stemming from warrants issued in a January 2026 private placement, creating a significant stock overhang.

check_boxKey Events

• Resale Registration for 3.96 Million Shares

  The company registered 3,964,712 shares of common stock for resale by Armistice Capital, LLC.

• Warrants from January 2026 Inducement

  These shares are issuable upon the exercise of Series A and Series B warrants, which were issued in a private placement that closed on January 20, 2026.

• Potential Future Proceeds to Company

  Vivos Therapeutics could receive approximately $8.29 million if the warrants are exercised for cash at their $2.09 per share exercise price.

• Significant Stock Overhang

  The registration of these shares, representing a substantial percentage of outstanding stock, creates a significant overhang, particularly as the warrants are currently out-of-the-money and the stock is trading near its 52-week low.

auto_awesomeAnalysis

This S-3 filing registers 3.96 million shares of common stock for resale by institutional investor Armistice Capital, LLC. These shares are issuable upon the exercise of Series A and Series B warrants, which were issued as part of a warrant inducement private placement that closed on January 20, 2026. While the company will not receive proceeds from the resale, it could receive approximately $8.29 million if the warrants are exercised for cash at their $2.09 per share exercise price. The registration of such a substantial number of shares, representing a significant portion of the company's outstanding stock, creates a considerable overhang on the stock, especially as the current stock price ($1.46) is below the warrant exercise price, and the company is trading near its 52-week low. This follows the 8-K filing on January 20, 2026, which disclosed the issuance of these warrants.